Additionally, PD-1 expression on effector T cells is elevated in a number of autoimmune diseases (15–17), and administration of PD-1 pathway antagonists can cause autoimmune-like symptoms in cancer patients, including aggravation of preexisting autoimmunity (18, 19). This evidence concerns the gene PDCD1 and autoimmune disease.